4DMedical’s Rapid US Expansion Raises Questions on Commercial Scalability
UC San Diego Health has begun clinical use of 4DMedical’s CT – VQ™, marking the fourth leading US academic medical centre to adopt this innovative lung imaging technology since FDA clearance. This milestone underscores 4DMedical’s rapid commercial traction and growing influence in respiratory diagnostics.
- UC San Diego Health initiates clinical use of CT – VQ™ under introductory pricing
- Fourth top-tier US academic medical centre to deploy CT – VQ™ since FDA approval
- CT, VQ™ offers contrast-free, high-resolution functional lung imaging
- Rapid adoption validates 4DMedical’s commercialisation strategy
- Partnerships and SaaS delivery model support scalable market expansion
A New Chapter in Lung Imaging
4DMedical Limited (ASX – 4DX) has secured another significant endorsement for its CT – VQ™ technology with UC San Diego Health commencing clinical use. This follows a rapid rollout to three other prestigious US academic medical centres, Stanford, University of Miami, and Cleveland Clinic, since the technology’s FDA clearance in August 2025. UC San Diego Health’s adoption not only expands the footprint of CT – VQ™ but also reinforces its status as a breakthrough in functional lung imaging.
Why CT – VQ™ Matters
CT – VQ™ represents a leap forward by providing detailed ventilation and perfusion imaging without the need for radioactive tracers or contrast agents. This contrast-free approach reduces patient risk and streamlines workflow by integrating seamlessly into existing CT imaging systems. The technology’s superior image resolution compared to traditional nuclear medicine scans offers clinicians enhanced diagnostic sensitivity and specificity, a critical advantage in managing complex lung diseases.
Strategic Validation Through Elite Partnerships
UC San Diego Health, ranked consistently among the top 10 US centres for pulmonology and lung surgery, brings considerable clinical prestige. Led by Dr Jonathan Chung, a pioneer in cardiothoracic imaging, the centre’s endorsement signals strong clinical confidence in CT – VQ™. The strategy of anchoring adoption within elite academic medical centres is proving effective, creating influential reference sites that accelerate physician education and broader market acceptance.
Commercial Momentum and Future Outlook
The initial deployment at UC San Diego Health is under an introductory pricing arrangement through March 2026, after which full commercial terms will apply. This phased approach supports early clinical integration while paving the way for sustainable revenue streams. Combined with 4DMedical’s partnership with Philips and its SaaS delivery model, the company is well-positioned to scale adoption and redefine standards in pulmonary imaging globally.
Looking Ahead
As 4DMedical continues to build momentum, the coming months will be critical for translating clinical validation into commercial success. The expanding network of top-tier academic centres not only strengthens the company’s market position but also sets the stage for potential reimbursement pathways that could accelerate widespread clinical adoption.
Bottom Line?
With four leading US centres now onboard, 4DMedical’s CT, VQ™ is poised to reshape lung imaging standards in 2026 and beyond.
Questions in the middle?
- How will transitioning from introductory pricing to full commercial terms impact 4DMedical’s revenue?
- What clinical outcomes data will emerge from these early adopter centres to support broader adoption?
- How quickly can 4DMedical expand beyond academic centres into community hospitals and international markets?
